Clinical Trial Update: Nivolumab in Combination With TACE/TAE for Patients With Intermediate Stage HCC [Phase 2, Phase 3]

View source ↗

Summary

The study evaluating nivolumab in combination with transarterial chemoembolization/chemoembolization for intermediate-stage hepatocellular carcinoma has been su…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• nivolumab (nivolumab)

Snippet

Sponsor: The Clatterbridge Cancer Centre NHS Foundation Trust | Conditions: Hepatocellular Carcinoma | Phase 2, Phase 3 | Status: SUSPENDED